Wasaburo Koizumi

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

Wasaburo Koizumi, Hiroyuki Narahara, Takuo Hara et al. · The Lancet Oncology · 2008 · 1.9K citations

Surgical Oncology, Spirits Trial, Gastrointestinal Oncology +8

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

Narikazu Boku, Seiichiro Yamamoto, Haruhiko Fukuda et al. · The Lancet Oncology · 2009 · 591 citations

Oncology, Cisplatin Versus S-1, Gastrointestinal Oncology +8

Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer

Wasaburo Koizumi, Minoru Kurihara, Shuji Nakano et al. · Oncology · 2000 · 440 citations

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

Wasaburo Koizumi, Satoshi Tanabe, Katsunori Saigenji et al. · British Journal of Cancer · 2003 · 249 citations · Full text

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial

Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 215 citations

Gastrointestinal Oncology, Medicine, Advanced Gastric Cancer +5